Doxylamine (Unisom) with Metoprolol: Safety and Monitoring
Doxylamine can be used with metoprolol, but requires caution due to a clinically significant drug interaction mediated through CYP2D6 inhibition that can increase metoprolol levels and risk of excessive beta-blockade.
The Drug Interaction Mechanism
Doxylamine, like diphenhydramine (another antihistamine), inhibits the CYP2D6 enzyme that metabolizes metoprolol. Research demonstrates that diphenhydramine coadministration with metoprolol caused a 2.2- to 3.2-fold decrease in metoprolol clearance, resulting in a 21% increase in heart rate reduction effects 1. While this study specifically examined diphenhydramine, doxylamine shares similar antihistamine properties and CYP2D6 inhibitory effects 2.
More concerning, a large California Medicaid study of 21,292 patients found that combining CYP2D6-inhibiting medications with beta-blockers like metoprolol increased the risk of hospitalization or emergency department visits for hemodynamic events (hypotension, bradycardia, falls) by 53% within 30 days (HR 1.53,95% CI 1.03-2.81) 3.
Clinical Risks to Monitor
The FDA label for metoprolol explicitly warns about bradycardia, including sinus pause, heart block, and cardiac arrest 4. When combined with CYP2D6 inhibitors like doxylamine, these risks are amplified:
- Bradycardia (heart rate <50 bpm)
- Hypotension (systolic BP <90 mm Hg)
- Heart block (particularly in patients with first-degree AV block or conduction disorders)
- Falls (especially in elderly patients)
- Worsening heart failure symptoms
Specific Monitoring Requirements
If this combination must be used:
- Check baseline vital signs before starting doxylamine: heart rate, blood pressure, and ECG if patient has any conduction abnormalities
- Monitor heart rate and blood pressure within 24-48 hours of starting doxylamine
- Watch for symptoms of excessive beta-blockade: dizziness, lightheadedness, fatigue, shortness of breath, cold extremities
- Consider reducing metoprolol dose by 25-50% when initiating doxylamine, especially if patient is on higher doses (>100 mg daily)
- Use the lowest effective dose of doxylamine for the shortest duration
High-Risk Patients Requiring Extra Caution
Based on the Medi-Cal study 3, these patients face increased risk:
- Advanced age (>65 years)
- Male sex
- Higher metoprolol doses (>100 mg daily)
- African American or Hispanic ethnicity
- Pre-existing bradycardia or conduction disease 4
- Heart failure (Killip Class II or III)
- Concurrent use of other rate-lowering agents (diltiazem, verapamil, digoxin, amiodarone) 5, 6
Safer Alternatives to Consider
Instead of doxylamine with metoprolol:
- Use a non-CYP2D6 metabolized beta-blocker like atenolol or bisoprolol if beta-blockade is needed 7
- Consider melatonin or behavioral interventions for insomnia
- If antihistamine sedation is necessary, use it only occasionally rather than chronically
- Discuss with prescriber whether metoprolol can be temporarily held or dose-reduced during short-term doxylamine use
Bottom Line Algorithm
- Avoid this combination if possible - seek alternative sleep aids
- If combination necessary: Reduce metoprolol dose by 25-50%, especially if >100 mg daily
- Monitor closely: Check HR/BP within 24-48 hours, then weekly for first month
- Stop doxylamine immediately if HR <50 bpm, SBP <90 mm Hg, or symptoms of excessive beta-blockade develop
- Limit duration: Use doxylamine for shortest time possible (days, not weeks)
The 4.3% rate of serious hemodynamic events within 30 days in the Medi-Cal study 3 represents a clinically meaningful risk that warrants careful consideration before combining these medications.